GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Gross Profit

BRAIN Biotech AG (XTER:BNN) Gross Profit : €31.39 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Gross Profit?

BRAIN Biotech AG's gross profit for the three months ended in Mar. 2024 was €8.44 Mil. BRAIN Biotech AG's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €31.39 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BRAIN Biotech AG's gross profit for the three months ended in Mar. 2024 was €8.44 Mil. BRAIN Biotech AG's Revenue for the three months ended in Mar. 2024 was €14.47 Mil. Therefore, BRAIN Biotech AG's Gross Margin % for the quarter that ended in Mar. 2024 was 58.29%.

BRAIN Biotech AG had a gross margin of 58.29% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 9 years, the highest Gross Margin % of BRAIN Biotech AG was 56.69%. The lowest was 48.02%. And the median was 54.44%.


BRAIN Biotech AG Gross Profit Historical Data

The historical data trend for BRAIN Biotech AG's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Gross Profit Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross Profit
Get a 7-Day Free Trial Premium Member Only 21.11 21.20 21.57 27.45 30.12

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.19 7.50 8.31 7.14 8.44

Competitive Comparison of BRAIN Biotech AG's Gross Profit

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Gross Profit Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Gross Profit distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Gross Profit falls into.



BRAIN Biotech AG Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BRAIN Biotech AG's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as

Gross Profit (A: Sep. 2023 )=Revenue - Cost of Goods Sold
=55.335 - 25.213
=30.12

BRAIN Biotech AG's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=14.474 - 6.037
=8.44

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €31.39 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BRAIN Biotech AG's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=8.44 / 14.474
=58.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BRAIN Biotech AG  (XTER:BNN) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BRAIN Biotech AG had a gross margin of 58.29% for the quarter that ended in Mar. 2024 => Durable competitive advantage


BRAIN Biotech AG Gross Profit Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines